Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human EZH2 Antibodies:
anti-Mouse (Murine) EZH2 Antibodies:
anti-Rat (Rattus) EZH2 Antibodies:
Go to our pre-filtered search.
Human Polyclonal EZH2 Primary Antibody for ChIPSeq, ChIP - ABIN2668958
Knutson, Kawano, Minoshima, Warholic, Huang, Xiao, Kadowaki, Uesugi, Kuznetsov, Kumar, Wigle, Klaus, Allain, Raimondi, Waters, Smith, Porter-Scott, Chesworth, Moyer, Copeland, Richon, Uenaka, Pollock et al.: Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. ... in Molecular cancer therapeutics 2014
Show all 9 Pubmed References
Human Monoclonal EZH2 Primary Antibody for ChIP - ABIN2668955
Bengani, Mendiratta, Maini, Vasanthi, Sultana, Ghasemi, Ahluwalia, Ramachandran, Mishra, Brahmachari: Identification and Validation of a Putative Polycomb Responsive Element in the Human Genome. in PLoS ONE 2013
Show all 8 Pubmed References
Human Polyclonal EZH2 Primary Antibody for WB - ABIN2668957
Izzo, Mercogliano, Venturutti, Tkach, Inurrigarro, Schillaci, Cerchietti, Elizalde, Proietti: Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth. in Breast cancer research : BCR 2015
Show all 7 Pubmed References
Human Polyclonal EZH2 Primary Antibody for WB - ABIN2668964
Kaneko, Li, Son, Xu, Margueron, Neubert, Reinberg: Phosphorylation of the PRC2 component Ezh2 is cell cycle-regulated and up-regulates its binding to ncRNA. in Genes & development 2010
Show all 2 Pubmed References
Polyclonal EZH2 Primary Antibody for WB - ABIN540724
Hobert, Jallal, Ullrich: Interaction of Vav with ENX-1, a putative transcriptional regulator of homeobox gene expression. in Molecular and cellular biology 1996
Show all 3 Pubmed References
Chicken Monoclonal EZH2 Primary Antibody for IF, WB - ABIN968906
Raaphorst, Otte, van Kemenade, Blokzijl, Fieret, Hamer, Satijn, Meijer: Distinct BMI-1 and EZH2 expression patterns in thymocytes and mature T cells suggest a role for Polycomb genes in human T cell differentiation. in Journal of immunology (Baltimore, Md. : 1950) 2001
Show all 2 Pubmed References
Chicken Monoclonal EZH2 Primary Antibody for IF, WB - ABIN968907
van Kemenade, Raaphorst, Blokzijl, Fieret, Hamer, Satijn, Otte, Meijer: Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. in Blood 2001
Show all 2 Pubmed References
Human Monoclonal EZH2 Primary Antibody for IF, IHC (p) - ABIN659002
Tsai, Manor, Wan, Mosammaparast, Wang, Lan, Shi, Segal, Chang: Long noncoding RNA as modular scaffold of histone modification complexes. in Science (New York, N.Y.) 2010
Show all 6 Pubmed References
Human Polyclonal EZH2 Primary Antibody for ICC, IF - ABIN438771
Hyland, McDade, McCloskey, Dickson, Arthur, McCance, Patel: Evidence for alteration of EZH2, BMI1, and KDM6A and epigenetic reprogramming in human papillomavirus type 16 E6/E7-expressing keratinocytes. in Journal of virology 2011
Study shows that the PRC2 core components are enriched in retinal progenitors and downregulated in differentiated cells. Knockdown of the PRC2 core component Ezh2 leads to reduced retinal progenitor proliferation.
Upregulated long non-coding RNA AGAP2 (show AGAP2 Antibodies)-AS1 (show PTGDR Antibodies) represses LATS2 (show LATS2 Antibodies) and KLF2 (show KLF2 Antibodies) expression through interacting with EZH2 and LSD1 (show KDM1A Antibodies) in non-small-cell lung cancer cells.
These findings elucidate a mechanism by which EZH2 and BCL6 (show BCL6 Antibodies) cooperate to repress bivalent promoters in germinal center B cells, and provide a rationale for combined treatment with EZH2 and BCL6 (show BCL6 Antibodies) inhibitors in patients with DLBCL.
EZH2 has prognostic value and may play an oncogenic role in Merkel cell carcinoma.
The increased expression of p21 (show CDKN1A Antibodies) and p27 (show PAK2 Antibodies) upon MALAT1 knockdown was regulated by enhancer of zeste homolog 2 (EZH2).
Study corroborated that EZH2 mRNA expression is increased in MPNST but failed to confirm its reported pivotal role in MPNST pathogenesis as EZH2 knockdown by siRNA did not interfere with cellular proliferation and viability.
NEK2 (show NEK2 Antibodies) has a role in maintaining glioma stem cells in glioblastoma by stabilizing the EZH2 protein
Study suggests a mechanism for EZH2-H3K27me3 epigenetic repression of DLC1 (show DYNLL1 Antibodies) and multilayered regulation of DLC1 (show DYNLL1 Antibodies)/Rho/ROCK signaling by EZH2, and advocated the significant pro-metastatic role of EZH2 via repressing tumor and metastasis suppressors.
EZH2 overexpression in human pituitary adenomas, especially invasive adenomas, and regulates tumor invasiveness, proliferation, and angiogenesis.
miR (show MLXIP Antibodies)-34a expression is silenced epigenetically by EZH2 and DNA methylation (show HELLS Antibodies), which promotes cholangiocarcinoma cell growth through activation of the Notch (show NOTCH1 Antibodies) pathway.
Ezh2(Y641F) induces lymphoma and melanoma through a vast reorganization of chromatin structure
High EZH2 expression is associated with Neuroblastoma (show ARHGEF16 Antibodies).
Biochemical as well as functional experiments revealed that Spt6 (show SUPT6H Antibodies) could compete for binding of the PRC2 methyltransferase Ezh2 to Suz12 (show SUZ12 Antibodies) and reduce PRC2 chromatin engagement.
These findings indicate that Ezh2 targets are the major targets of the epigenetic switch in MDS (show MECOM Antibodies) with Ezh2 insufficiency.
Insight regarding how androgen-induced extranuclear kinase signaling and intranuclear transcription through Ezh2 modifications may influence the expression pattern of genes, ultimately affecting various downstream physiological processes.
results uncover a crucial role for EZH2 in adaptive lymphocytes to control the developmental timing of effectors of the pre-Ag receptor checkpoints
These findings identify the Ezh2-Hsp90 (show HSP90 Antibodies) interaction as a previously unrecognized mechanism essential for T-cell responses and an effective target for controlling graft-versus-host disease.
Eed (show EED Antibodies) and Ezh2 have distinct roles in urothelial differentiation
Findings uncover an Ezh2-dependent mechanism to restrict the smooth muscle gene expression program in the developing mesothelium and allow appropriate cell fate decisions to occur in this multipotent mesoderm lineage.
The evidence has been presented that the retinoblastoma protein utilizes a cell-cycle-independent interaction with E2F1 (show E2F1 Antibodies) to recruit EZH2 to diverse repeat sequences.
This study identified Ezh2 as enriched in melanoma cancer stem cells (MCS (show SMCP Antibodies) cells) and showed that Ezh2 knockdown or treatment with small molecule Ezh2 inhibitors reduces MCS (show SMCP Antibodies) cell spheroid formation, survival, invasion and migration.
This gene encodes a member of the Polycomb-group (PcG) family. PcG family members form multimeric protein complexes, which are involved in maintaining the transcriptional repressive state of genes over successive cell generations. This protein associates with the embryonic ectoderm development protein, the VAV1 oncoprotein, and the X-linked nuclear protein. This protein may play a role in the hematopoietic and central nervous systems. Multiple alternatively splcied transcript variants encoding distinct isoforms have been identified for this gene.
enhancer of zeste 2
, enhancer of zeste homolog 2 (Drosophila)
, Polycomb protein EZH2
, histone-lysine N-methyltransferase EZH2
, histone-lysine N-methyltransferase EZH2-like
, Enhancer of zeste homolog 2-A
, Polycomb protein EZH2-A
, lysine N-methyltransferase 6
, enhancer of zeste homolog 2
, eyes absent homolog 2